WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
As on 02 Apr 2025

WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
EquityNAV
₹ 12.85
CAGR (3 Years)
%
AUM (Cr)
₹ 271.36
Risk
Very High Risk
About WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Breakdown of this Fund
Chemicals
3.21%
Debt Others
8.47%
Healthcare
52.06%
IT - Software
0.49%
Miscellaneous
1.13%
Pharmaceuticals
88.78%
Plastic products
1.45%
T Bills
6.60%